1. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Issue 8 (August 2020) Authors: Smith, Jaclyn A; Kitt, Michael M; Morice, Alyn H; Birring, Surinder S; McGarvey, Lorcan P; Sher, Mandel R; Li, Yu-Ping; Wu, Wen-Chi; Xu, Zhi Jin; Muccino, David R; Ford, Anthony P; Smith, Jaclyn; McGarvey, Lorcan; Birring, Surinder; Hull, James; Carr, Warner W; Goldsobel, Alan B; Gross, Gary N; H... Journal: Lancet Issue: Volume 8:Issue 8(2020) Page Start: 775 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗